Skip to content
Screener

Insulet PODD Proceeds from issuance of common stock under employee stock purchase plan

Proceeds from issuance of common stock under employee stock purchase plan at other companies

Lifevantage Corporation logo
Lifevantage CorporationLFVN
$84K-42.9%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
$354K+13.1%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
$354K+13.1%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$3.39M+81.9%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$839K-39.6%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$839K-39.6%

Other financials

Income statement

See full
Revenue$801.7M+23.5%
Gross profit$562.6M+24.4%
Operating income$129.7M+7.1%
Net income$95.0M+322%
EPS (diluted)$1.37+328%

Balance sheet

See full
Cash & equivalents$534.9M-52.3%
Total debt$974.7M-47.6%
Total equity$1.4B-2.8%
Total assets$3.2B-8.8%

Cash flow

See full
Operating cash flow$88.4M-55.0%
CapEx$32.5M+74.7%
Free cash flow$55.9M-68.6%

Valuation

See full
Market cap$9.79B-53.8%
Enterprise value$10.23B-53.4%
P/E26.1×-63.7×
P/S3.2×-5.8×

Profitability

See full
Gross margin71.1%+0.3pp
Operating margin16.9%-0.4pp
Net margin12.3%+2.3pp
FCF margin9.6%-7.5pp

Returns & leverage

See full
Return on equity26%+6.8pp
Debt / equity0.7×-0.6×
Current ratio2.5×+0.2×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept podd:ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan.

The source filing: Insulet’s 10-K, filed February 18, 2026.

Filed
Feb 18, 2026, 4:03 PM EST
Fiscal year
FY2025
Accession
0001145197-26-000028
(in millions)Years Ended December 31, 2025Years Ended December 31, 2024Years Ended December 31, 2023
Settlement of capped call options164.6
Repurchase of common stock(59.6)
Proceeds from exercise of stock options19.08.216.3
Proceeds from issuance of common stock under employee stock purchase plan14.911.910.6
Payment of withholding taxes in connection with vesting of restricted stock units(25.9)(7.6)(13.2)
Other(0.3)
Net cash used in financing activities(595.3)(28.0)(13.6)
Effect of exchange rate changes on cash and cash equivalents11.5(6.8)1.8

Item 8. Financial Statements and Supplementary Data

FAQ

What is Insulet's proceeds from issuance of common stock under employee stock purchase plan?
Insulet (PODD) reported proceeds from issuance of common stock under employee stock purchase plan of $7.8M in Q4 2025.
How has Insulet's proceeds from issuance of common stock under employee stock purchase plan changed year-over-year?
Insulet's proceeds from issuance of common stock under employee stock purchase plan increased by 32.2% year-over-year, from $5.9M to $7.8M.
What does proceeds from issuance of common stock under employee stock purchase plan mean?
Proceeds from issuance of common stock under employee stock purchase plan as reported by Insulet Corporation.

Ask your AI about Insulet's proceeds from issuance of common stock under employee stock purchase plan.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude